Vimarsana
Biggest News Aggregation in the World

Model Informed Drug Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Model Informed Drug Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Model Informed Drug Development Today - Breaking & Trending Today

Applied BioMath, LLC Hosts 6th Annual Quantitative Systems Pharmacology Summit - Vimarsana News

Applied BioMath, LLC Hosts 6th Annual Quantitative Systems Pharmacology Summit

/PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help...

Anebulo Pharmaceuticals: providing an effective antidote for cannabis intoxication - Vimarsana News

Anebulo Pharmaceuticals: providing an effective antidote for cannabis intoxication

Anebulo Pharmaceuticals is currently developing a new, first-of-its-kind drug, ANEB-001, intended to rapidly reverse the negative effects of ACI within one hour of administration. The treatment is a cannabinoid receptor antagonist, which blocks THC, the substance which gives cannabis its psychotropic effects, from binding in a person’s CB1 receptor.

FDA On Use Of AI/ML In Drug Development: Five Key Takeaways - Life Sciences, Biotechnology & Nanotechnology - Vimarsana News

FDA On Use Of AI/ML In Drug Development: Five Key Takeaways - Life Sciences, Biotechnology & Nanotechnology

On Wednesday, May 10, 2023, the Food and Drug Administration (FDA) announced the publication of a new discussion paper titled "Using Artificial Intelligence and Machine Learning in the Development...

Source: mondaq.com
Simulations Plus, Inc. (SLP) Q4 2022 Earnings Call Transcript - Vimarsana News

Simulations Plus, Inc. (SLP) Q4 2022 Earnings Call Transcript

Simulations Plus, Inc. (NASDAQ:NASDAQ:SLP) Q4 2022 Earnings Conference Call October 26, 2022 5:00 PM ET Company Participants Brian Siegel – Hayden IR Shawn O’Connor – Chief Executive...

Akari Therapeutics Plc: Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress - Vimarsana News

Akari Therapeutics Plc: Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports Akari's focused pipeline including